Quantcast
Last updated on April 21, 2014 at 12:45 EDT

Radient Pharmaceuticals Submits an Abstract to the American Society of Colon and Rectal Surgeons

December 8, 2011

TUSTIN, Calif., Dec. 8, 2011 /PRNewswire/ — Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), developer and marketer of the Onko-Sure® In Vitro Diagnostic (IVD) cancer test, announced today that it has submitted one abstract for the American Society of Colon and Rectal Surgeons’ (ASCRS) Annual Meeting to be held in June 2012. ASCRS is the premier society for colon and rectal surgeons and other surgeons dedicated to advancing and promoting the science and practice of the treatment of patients with disease and disorders affecting the colon, rectum and anus.

The title of the abstract submitted is “Combined DR-70 and CEA testing is advantageous over CEA alone in the detection of colorectal cancer and specially the right-sided type.” More than 1,000 of the Society’s members are certified by the American Board of Colon and Rectal Surgery. The meeting will be held from June 2nd to 6th, 2012 in San Antonio, TX. Over 1,200 surgeons are expected to attend.

If accepted, Robert Beart Jr., M.D., who was appointed to the Company’s Board of Directors in June 2010, will make the Company presentation. Dr. Beart currently is the medical director of the Glendale Hospital CRC Institute. Previously he was with the University of Southern California since 1992, establishing the Division of Colorectal Surgery in the USC Department of Surgery as well as launching the USC Center for Colorectal Diseases at USC University Hospital and USC/Norris Cancer Center and Hospital.

Dr. Beart is a recognized specialist and expert in colorectal diseases and cancer, pioneer of the ileal pouch-anal anastomosis, and thought leader in the medical, scientific and research communities. Dr. Beart’s primary experience and research includes the identification and management of recurrent colorectal cancer. He has broad and deep clinical involvement in colorectal diseases, covering key areas that include colorectal cancer, chronic constipation and diarrhea, anorectal health care issues and diverticulitis, fecal incontinence, recurrent rectal cancer, inflammatory bowel disease and polyps. From 1976 through 1992 Dr. Beart worked at the Mayo Clinic in Rochester, Minnesota where he was Chairman of Department of Colorectal Surgery and pioneered the ileal pouch-anal anastomosis. He is a past president of the American Society of Colon and Rectal Surgeons, the Society of Surgery of the Alimentary Tract and the International Society of University Colorectal Surgeons.

“Onko-Sure® has been cleared by the U.S. Food and Drug Administration (FDA) for the monitoring of the treatment and recurrence in colorectal cancer and when used adjunctively with other available diagnostic markers, the number of annual deaths due to CRC recurrence could be reduced. An increase in early detection has the potential to lead to an increased survival rate of patients,” says Radient Pharmaceuticals Chairman and CEO Douglas MacLellan.

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Paul Knopick at: pknopick@eandecommunications.com or 949-707-5365.

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company’s focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Radient Contact:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
(Tel:) 949.707.5365

SOURCE Radient Pharmaceuticals Corporation


Source: PR Newswire